Editor-in-Chief
Hatice Kübra Elçioğlu
Vice Editors
Levent Kabasakal
Esra Tatar
Online ISSN
2630-6344
Publisher
Marmara University
Frequency
Bimonthly (Six issues / year)
Abbreviation
J.Res.Pharm.
Former Name
Marmara Pharmaceutical Journal
Journal of Research in Pharmacy
2024 , Vol 28 , Issue 2
Protein expression, crystallization and in-silico studies on cytochrome P450 Oxidoreductase wildtype and mutant variants
1PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam2School of Medical and Life Sciences, Sunway University, Sunway City, Selangor, Malaysia DOI : 10.29228/jrp.718 Cytochrome P450 oxidoreductase (POR) is a crucial membrane-bound enzyme that facilitates the transfer of electrons to all cytochrome P450 (CYP450) enzymes. Several mutations in the POR gene have been reported to cause cytochrome P450 oxidoreductase deficiency (PORD), an autosomal recessive genetic disorder. This study explored the consequences of seven POR missense mutations (Y181D, A287P, R457H, R498P, C569Y, Y607C, and H628P), which have been documented in PORD patients, on the structural integrity and stability of the POR enzyme in vitro. The comparison between these mutants and the wild-type POR focused on in vitro protein expression, purification, and crystallization characteristics. The mutation-induced alterations in the POR architecture significantly influenced the protein's expression and crystallization capabilities. The magnitude of these effects on the enzyme's behavior varied from moderate to severe, contingent on the mutation's nature and position. This research illuminates the influence of specific mutations on POR stability, underlining the necessity of understanding mutation-driven effects on enzyme stability to devise personalized therapeutic approaches for PORD patients. Future studies will involve the functional characterization of these mutant enzymes to further understand their impact on the POR enzyme's activity and stability. Keywords : Cytochrome P450 oxidoreductase (POR); cytochrome P450 oxidoreductase deficiency (PORD); POR protein expression; POR crystallization; POR mutants